DENIS LABORATORY — CANCER RESEARCH CENTER
GERALD V. DENIS
Scientific co-Director, Flow Cytometry Core, Boston University Medical Campus
Program in Molecular Medicine and Immunology Training Program
Section of Hematology/Oncology, Departments of Pharmacology and Medicine
Harvard College (A.B.)
University of Tokyo (M.Sc.)
University of California, Berkeley (Ph.D.)
1979–1981, Research assistant with Dr. Richard Wilson, Department of Physics, Harvard University. High Energy Physics Laboratory, Cambridge, MA
1981–1983, Research assistant with Dr. Elizabeth R. Simons, Department of Biochemistry, Boston University School of Medicine, Boston, MA
1983–1985, Research assistant with Dr. Toshiaki Osawa (Seitai Ibutsu Meneki Kagaku Kyoshitsu) University of Tokyo, Faculty of Pharmaceutical Sciences, Tokyo, Japan
1985–1990, Research assistant with Dr. Clinton E. Ballou, Department of Molecular and Cellular Biology, University of California, Berkeley, CA
1991–1996, Postdoctoral Fellow with Dr. Michael R. Green, Program in Molecular Medicine, University of Massachusetts and Howard Hughes Medical Institute, UMMC, Worcester, MA
1997–2000, Instructor in Medicine, Cancer Research Center, Boston University School of Medicine (BUSM)
2000–present, Assistant Professor of Medicine, BUSM
2003–present, Assistant Professor of Pharmacology, BUSM
2003–present, Member and Instructor, Graduate Program in Molecular Medicine, BUSM
2005–present, Hematology Training Program affiliated faculty member, “Research Training Program in Blood Diseases and Resources”, T32 HL07501, BUSM
2006–present, Scientific co-Director, Flow Cytometry Core Facility, Boston University Medical Campus
2007–present, Immunology Training Program affiliated faculty member, “Research Program in Immunology”, T32 AI007309, BUSM
2008–present, Boston Nutrition Obesity Research Center affiliated faculty member, Boston University Medical Campus
2010–present, Associate Professor, BUSM
1983, Tokyo Biochemical Society Scholarship
1984, Yoneyama Rotary Foundation Fellowship, Tokyo
1997, NIH FIRST award
1997, Aid for Cancer Research Award
2004, American Cancer Society Research Scholar Award
2005, Jiler – American Cancer Society Professors Meeting, competitive abstract winner/participant
Recent and Upcoming Presentations
• Denis GV. (2009). Obesity Society 27th Annual Scientific Meeting, Washington, DC. October.
• Belkina AC, Wang F, Blanton WP, Liu H, Denis GV. (2010). Brd2 deficiency in macrophage function protects obese mice from insulin resistance. Keystone Conference on the macrophage: Intersection of pathogenic and protective inflammation. Banff, Alberta; February.
• Belkina AC, Wang F, Blanton WP, Liu H, Denis GV. (2010). Whole body Brd2 deficiency protects obese mice from insulin resistance by creating a low inflammatory environment. Obesity Society 28th Annual Scientific Meeting, San Diego, CA. October.
• Denis GV. (2011). Bromodomain coregulators in obesity, cancer and inflammation. Symposium on NF-κB, cancer, obesity and inflammation. Cincinnati Cancer Symposium Series, Cincinnati, OH. May.
• Belkina AC, Blanton WP, Denis GV. (2011). Failure of macrophage and adipocyte crosstalk in obesity protects obese Brd2 deficient mice from insulin resistance. Obesity Society 29th Annual Scientific Meeting, Orlando, FL. October.
Blanton WP *, Belkina AC*, Denis GV. (2011). The BET protein Brd2 regulates B cell expansion from hematopoietic stem cell progenitors. Under review.
Blanton WP*, Belkina AC*, Romesser PB, Denis GV. (2011). Aggressive diffuse large B-cell lymphomas of Eµ-Brd2 transgenic mice lack germinal center experience. Under review.
Ehrlich DJ, McKenna BK, Evans JG, Belkina AC, Denis GV, Sherr DH, Cheung MC. (2011). Parallel imaging microfluidic cytometer. Meth Cell Biol. 12: In press.
Denis GV. (2010). Bromodomain coactivators in cancer, obesity, type 2 diabetes and inflammation. Discov Med. 10:489–499.
Belkina AC, Denis GV. (2010). Obesity genes and insulin resistance. Curr Opin Endocrinol Diabetes Obes. 17:472–477.
Denis GV, Nikolajczyk BS, Schnitzler GR. (2010). An emerging role for bromodomain-containing proteins in chromatin regulation and transcriptional control of adipogenesis. FEBS Lett. 584:3260–3268.
Wang F, Liu H, Blanton WP, Belkina A, Lebrasseur NK, Denis GV. (2009). Brd2 disruption in mice causes severe obesity without type 2 diabetes. Biochem J. 425:71–83.
Longe HO, PB Romesser, AM Rankin, DV Faller, MS Eller, BA Gilchrest and GV Denis (2009). Telomere homolog oligonucleotides induce apoptosis in malignant but not in normal lymphoid cells: Mechanism and therapeutic potential. Int. J. Cancer. 124: 473–482.
Romesser PB, Perlman DH, Faller DV, Costello CE, McComb ME, Denis GV. (2009). Development of a malignancy-associated proteomic signature for diffuse large B cell lymphoma. Am J Pathol. 175:25–35.
Lenburg ME, Sinha A, Faller DV, Denis GV. (2007). Tumor-specific and proliferation-specific gene expression typifies murine transgenic B cell lymphomagenesis. J Biol Chem. 282:4803–4811.
Denis GV, McComb ME, Faller DV, Sinha A, Romesser PB, Costello CE (2006). Identification of transcription complexes that contain the double bromodomain protein Brd2 and chromatin remodeling machines. J Proteome Res. 5:502–511
You J, Srinivasan V, Denis GV, Harrington WJ Jr, Ballestas ME, Kaye KM, Howley PM. (2006). Kaposi’s Sarcoma-associated herpesvirus latency-associated nuclear antigen interacts with bromodomain protein Brd4 on host mitotic chromosomes. J Virol. 80:8909–8919.
Sinha A, Faller DV, Denis GV. (2005). Bromodomain analysis of Brd2-dependent transcriptional activation of cyclin A. Biochem J. 387:257–269.
Denis, G. V. (2007). Imatinib mesylate (Gleevec) and the emergence of chemotherapeutic drug-resistant mutations. In H. L. Kaufman, S. Wadler and K. H. Antman, Eds., Cancer Drug Discovery and Development; Specific Drugs for Molecular Targeting in Oncology, Part IV, Chapter 22. Humana Press; Totowa, NJ. In press.
T32 AI007272 (PI Ennis)
NIH (NIAID): Virus AIDS Pathogenesis and Host Defenses
R29 CA75107 FIRST award (PI Denis)
NIH (NCI): A Novel, Inducible Nuclear Kinase Linked to Leukemia
Cancer Center Pilot Grant (PI Denis)
Cancer Research Center, Boston University School of Medicine
Multiprotein Complexes in the Cell Cycle and Cancer
R03 CA102889 (PI Denis)
NIH (NCI): Biomarkers for Lymphoma in a New Transgenic Mouse Model
Undergraduate Research Opportunity Award (PI Denis)
Boston University: Proteomic Characterization of B cell Proliferative States
Undergraduate Research Opportunity Award
Boston University: Mass Spectrometric Analysis of Cell Cycle-Regulatory Transcription Complexes
R03 CA128006 (PI Denis)
NIH (NCI): Proteomic Biomarkers for Lymphoma
RSG-05-072-01 (PI Denis)
American Cancer Society: Molecular Analysis of Brd2 Signaling and B Cell Function
Pilot and Feasibility Award (PI Denis)
Boston Area Diabetes Endocrinology Research Center: The Role of Brd2 in Energy Homeostasis
P41 RR010888 (PI Costello)
NIH (NATIONAL CENTER FOR RESEARCH RESOURCES): Mass Spectrometry Resource for Biology and Medicine
Translational Award 6023-09 (PI Denis) Leukemia and Lymphoma Society
Telomere DNA-based, novel therapy for aggressive lymphoid malignancy
Evans Faculty Merit Award (PI Denis) Evans Medical Foundation
Whole body reduction of Brd2 protects against obesity-induced insulin resistance